Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Roivant's Sale Of Dermavant To Organon
Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click here to read my most recent analysis.
Organon to acquire Dermavant in $1.2B deal
The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.
Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to $1.2 Billion
Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on Wednesday said it will make an up-front payment of $175 million, along with up to $1.025 billion in milestone payments.
Organon to acquire Dermavant in back-loaded deal
Women’s health specialist Organon has entered into a definitive agreement to acquire Dermavant Sciences, a Roivant company.
Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary
As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis.
Organon to Buy Roivant's Dermatology Unit For Up to $1.2 Billion
Organon (OGN) on Wednesday agreed to acquire Roivant Sciences' (ROIV) immuno-dermatology subsidiary, Dermavant, in a deal worth up to $1.2 billion. The healthcare company will pay $175 million upfront and up to $950 million for the achievement of certain commercial milestones.
Pharmabiz
2h
Organon to buy Dermavant Sciences including its innovative dermatologic therapy, Vtama cream 1% to treat plaque psoriasis
Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...
pharmaphorum
1d
Organon makes dermatology play with $1.2bn Dermavant buyout
Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...
FiercePharma
1d
Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama
Organon
is set to acquire Roivant’s immuno-dermatology subsidiary
Dermavant
for up to $1.2 billion, the companies ...
23h
Assessing Organon’s Strategic Acquisition of Dermavant: A Balanced Hold Recommendation Amid Growth and Challenges
Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of ...
BioWorld
1d
Skin deep: Organon buys Dermavant for $1.2B
Roivant Sciences Ltd. has sold another company, this time offering up Dermavant Sciences Ltd. to Organon & Co. for $1.2 ...
Armed robbery in Revesby
1d
Organon Acquires Dermavant and VTAMA Therapy
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional ...
1d
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Roivant
Vtama
Food and Drug Administration
Feedback